AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Haleon (HLN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

9.97

0.26 (2.68%)

At close: Feb 18, 2025, 3:59 PM

9.99

0.15%

After-hours: Feb 18, 2025, 07:00 PM EST

undefined% (undefined)

Bid	9.55
Market Cap	45.15B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.33
PE Ratio (ttm)	30.23
Forward PE	n/a
Analyst	Buy

Ask	10.06
Volume	8,863,042
Avg. Volume (20D)	8,676,400
Open	10.02
Previous Close	9.71
Day's Range	9.93 - 10.06
52-Week Range	7.89 - 10.80
Beta	undefined

About HLN

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensod...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Jul 25, 2022

Employees 25,408

Stock Exchange NYSE

Ticker Symbol HLN

Website https://www.haleon.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for HLN stock is "Buy." The 12-month stock price forecast is $10.47, which is an increase of 4.96% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Haleon is scheduled to release its earnings on Mar 3, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

11 months ago

-2.29%

Haleon shares are trading lower after Pfizer annou... Unlock content with Pro Subscription

News

3 weeks ago · reuters.com

Haleon to invest $54 mln in US R&D centre to boost product innovation

Consumer healthcare company Haleon said on Wednesday it will invest $54 million in its global research and development centre in Richmond, U.S., aiming to boost its pipeline for new product innovation...

3 weeks ago · zacks.com

AHCO vs. HLN: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Products stocks have likely encountered both AdaptHealth Corp. (AHCO) and Haleon PLC Sponsored ADR (HLN). But which of these two companies is the best option fo...

1 month ago · proactiveinvestors.co.uk

Pfizer to further reduce stake in Haleon through share sale

Pfizer Inc (NYSE:PFE, ETR:PFE) plans to sell around 700 million shares of Haleon PLC (LSE:HLN, NYSE:HLN), representing a 7.7% stake, via a secondary offering through an accelerated book-building proce...

1 month ago · wsj.com

Pfizer Sells 700 Million Haleon Shares for $3 Billion

The sale decreases Pfizer's shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from 15%.

1 month ago · reuters.com

Pfizer intends to cut stake in Sensodyne-maker Haleon to 7.3%, says bookrunner

Pfizer intends to sell about 700 million ordinary shares in Haleon , cutting its stake to about 7.3% in the British consumer healthcare group, a bookrunner said on Tuesday.

2 months ago · seekingalpha.com

Haleon: Guidance Implies Uncertainty Around Flu Season

Haleon plc is logging solid organic performances led by their solid brand portfolio for oral health with brands like Sensodyne and Parodontax. This is despite some tough comps still in the results, pa...